Lipoxen Raises £2.6 Million Through Strategic Placing And Warrant Agreement With Serum Institute of India, Ltd.
Lipoxen PLC (AIM: LPX), a biopharmaceutical company specialising in the development of differentiated biologicals, vaccines and oncology drugs, today announced that it had raised £2.6 million in new funds from the Serum Institute of India Limited ("SIIL") through a subscription agreement and associated warrant agreement.